The DEA Started a 30-Day Clock on Banning Concentrated Kratom Extracts. Whole-Leaf Kratom Isn't What's on Trial.

The DEA opened a Notice of Intent on July 1 to temporarily place 7-hydroxymitragynine — known as 7-OH, a concentrated, chemically enhanced kratom derivative — into Schedule I, alongside three related synthetic compounds. HHS and FDA issued a same-day statement backing the move, citing rising reports of misuse, dependence, and overdose tied to concentrated 7-OH products increasingly sold as gas-station and smoke-shop supplements. A 30-day public comment period followed, and a formal temporary scheduling order could land as early as August 5.

The line the DEA drew is narrower than the headlines about it — and that line is the part worth actually reading.

The proposed threshold is specific: 0.050% dry weight for botanical (leaf) products, or 0.050%/1.00 milligram for synthetically produced extracts, edibles, and pills. Natural leaf kratom that doesn’t cross that concentration line is explicitly excluded from the scheduling action. That distinction matters because it’s not the one most coverage of “kratom getting banned” is making. The product being targeted is the engineered, high-concentration extract category — closer in intent to a synthetic opioid analog than to the ground-leaf tea kratom’s traditional users have relied on for pain, opioid withdrawal management, and energy.

That said, the underlying harm signal is real and has been building for a while. CDC’s MMWR reports kratom-related poison-control calls rose roughly 1,200% over the past decade — still a small fraction of the estimated five million people who use kratom in some form, but a genuinely steep curve, and one concentrated disproportionately in exactly the enhanced-extract category the DEA is now moving against.

If you or someone you’re treating uses kratom regularly: the practical question this month isn’t “is kratom illegal now” — it isn’t, and whole-leaf product isn’t the target. It’s whether what’s actually in the package crosses a concentration line most users have never been told to check for. Enhanced 7-OH extracts are marketed and packaged to look identical to traditional kratom powder. They are not the same product, and this is the first time federal policy has drawn a hard line distinguishing them.

The comment period runs through the end of July, and the practical window for anyone who wants to weigh in — a treatment provider, a kratom vendor, a person relying on it to manage opioid withdrawal without returning to something stronger — is closing fast. Whatever the final order says on August 5, the products already sitting on smoke-shop shelves today aren’t going to relabel themselves.